SG&A as a percentage of revenue 50.9 % 47.2 % SG&A expenses increased by $38.5 million, or 24.1%, to $198.5 million in the three months ended June 30, 2026, from $160.0 million in the three months ended June 30, 2025.

filing / Jul 30, 2026 / receipt

SG&A as a percentage of revenue 51.2 % 47.3 % SG&A expenses increased by $77.9 million, or 24.8%, to $391.3 million in the six months ended June 30, 2026, from $313.4 million in the six months ended June 30, 2025.

filing / Jul 30, 2026 / receipt

The increase was primarily due to a $11.7 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, a $6.9 million increase in acquisition-related expenses primarily attributable to professional services associated with the pending acquisition of our Company by Boston Scientific Corporation, a $6.8 million increase in costs related to marketing event

filing / Jul 30, 2026 / receipt

The increase was primarily due to a $3.0 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, partially offset by a $0.5 million decrease in other research and development activities due to the timing of planned investments.

filing / Jul 30, 2026 / receipt

SG&A as a percentage of revenue 51.4 % 47.3 % SG&A expenses increased by $39.3 million, or 25.6%, to $192.8 million in the three months ended March 31, 2026, from $153.5 million in the three months ended March 31, 2025.

filing / May 6, 2026 / receipt

The increase was primarily due to a $17.2 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, a $9.4 million increase in acquisition-related expenses primarily attributable to professional services associated with the pending acquisition of our Company by Boston Scientific Corporation , and a $3.1 million increase in costs related to marketing

filing / May 6, 2026 / receipt

As we continue to invest in our growth, we have expanded and may continue to expand our sales, marketing, and general and administrative teams through the hiring of additional employees in critical roles that support our strategic initiatives.

filing / May 6, 2026 / receipt

Development Manufacturing Engineer I | {"ats": "lever", "city": "Alameda", "state": "CA", "job_id": "65977d1d-084e-4ec9-9009-aa9ab94b7d42", "remote": false, "category": "other", "function": "engineeri

company_statement / Sep 14, 2026 / receipt

Regulatory Affairs Specialist I | {"ats": "lever", "city": "Alameda", "state": "CA", "job_id": "b8a487f8-fbfb-4d9d-a53a-d1d093c23ec6", "remote": false, "category": "other", "function": "legal", "locat

company_statement / Sep 11, 2026 / receipt

Clinical Research Associate II (Field CRA) | {"ats": "lever", "city": null, "state": null, "job_id": "1086b77c-bc31-4fec-b417-013a2bcdd297", "remote": true, "category": "other", "function": "clinical"

company_statement / Sep 10, 2026 / receipt

Marketing Manager | {"ats": "lever", "city": "Alameda", "state": "CA", "job_id": "4f859c70-e739-4d05-b3b1-8042f8e019f2", "remote": false, "category": "other", "function": "marketing", "location": "Ala

company_statement / Sep 10, 2026 / receipt

Senior Accounts Payable Specialist (Temporary) | {"ats": "lever", "city": "Alameda", "state": "CA", "job_id": "9bf37a4f-1914-494b-a4b2-91a9c5fddf9c", "remote": false, "category": "finance_ops", "funct

company_statement / Sep 10, 2026 / receipt